Masimo (NASDAQ:MASI – Get Free Report)‘s stock had its “hold” rating reaffirmed by equities research analysts at Needham & Company LLC in a research report issued on Wednesday,Benzinga reports.

Masimo Corporation (NASDAQ:MASI), a medical technology company valued at $9.36 billion, reported on Friday the resignation of board member Robert Chapek. The departure is set to take effect on the ...

Sees FY25 operating margins at least 26.5%. Published first on TheFly – the ... performing stocks on TipRanks >> Read More on MASI: Masimo CorpShs NewsMORE Related Stocks Indices Commodities ...

Full-Year 2025 Guidance incorporates the financial impact of one additional calendar week for the healthcare business, which occurs every five or six years based on Masimo’s 4-4-5 fiscal ...

Looking ahead, for the full-year 2025, excluding items, Masimo expects income per share of $4.90 to $5.10, with adjusted operating profit of $398 million to $406 million, representing adjusted ...

For 2025, Masimo forecast healthcare revenue between $1.5 billion and $1.53 billion as well as adjusted earnings per-share in the range of $4.90 and $5.10. Write to Denny Jacob at denny.jacob@wsj ...

If you're looking for a fresh pick that's set to soar in the near-term, make sure to keep Masimo on your short list. Our team of experts has just released the 5 stocks with the greatest ...

Masimo appointed Katie Szyman as its next chief executive officer after a proxy fight forced out the company’s founder. Szyman will become CEO of the medical-device maker Feb. 12, replacing interim ...

Today the Board of Directors (the “Board”) of Masimo (NASDAQ: MASI), a leading global medical innovator, announced that Katie Szyman has been appointed the next Chief Executive Officer (“CEO ...